BridgeBio Pharma Long-Term Investments 2018-2026 | BBIO
BridgeBio Pharma long-term investments from 2018 to 2026. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
- BridgeBio Pharma long-term investments for the quarter ending March 31, 2026 were $0.062B, a 52% decline year-over-year.
- BridgeBio Pharma long-term investments for 2025 were $0.08B, a 44.37% decline from 2024.
- BridgeBio Pharma long-term investments for 2024 were $0.144B, a 0% decline from 2023.
- BridgeBio Pharma long-term investments for 2023 were $0B, a 0% decline from 2022.
|
BridgeBio Pharma Annual Long-Term Investments (Millions of US $) |
|
|---|---|
| 2025 | $80 |
| 2024 | $144 |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | $31 |
| 2018 | $17 |
| 2017 | |
|
BridgeBio Pharma Quarterly Long-Term Investments (Millions of US $) |
|
|---|---|
| 2026-03-31 | $62 |
| 2025-12-31 | $80 |
| 2025-09-30 | $92 |
| 2025-06-30 | $108 |
| 2025-03-31 | $128 |
| 2024-12-31 | $144 |
| 2024-09-30 | $160 |
| 2024-06-30 | $117 |
| 2024-03-31 | |
| 2023-12-31 | |
| 2023-09-30 | |
| 2023-06-30 | |
| 2023-03-31 | |
| 2022-12-31 | |
| 2022-09-30 | |
| 2022-06-30 | |
| 2022-03-31 | |
| 2021-12-31 | |
| 2021-09-30 | $18 |
| 2021-06-30 | $80 |
| 2021-03-31 | $82 |
| 2020-12-31 | |
| 2020-09-30 | |
| 2020-06-30 | |
| 2020-03-31 | $23 |
| 2019-12-31 | $31 |
| 2019-09-30 | $77 |
| 2019-06-30 | |
| 2019-03-31 | |
| 2018-12-31 | |
| 2018-09-30 | |
| 2017-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $14.460B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |